Sarepta Therapeutics Inc. (SRPT)
Better Biotech Stock: Wave Life Sciences vs. Sarepta Therapeutics
These two could become direct competitors relatively soon.
Sarepta Therapeutics Muscles Up In DMD Race
Sarepta's Elevidys received expanded FDA approval to treat both ambulatory and non-ambulatory DMD patients aged four and above. Although Elevidys missed its primary endpoint, it demonstrated success on secondary measures like motor function improvement and time-to-rise. SRPT expects substantial revenue growth, projecting net product revenues of $2.9-3.1 billion by 2025.
These 2 Biotech Stocks Are Set to Soar
Viking Therapeutics is inching closer to launching a weight loss product with multibillion-dollar potential. Sarepta Therapeutics continues to develop medicines for rare diseases whose sufferers have few options.
Why Is Sarepta Therapeutics (SRPT) Down 1.9% Since Last Earnings Report?
Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock?
Bull Signal Flashing for Sarepta Therapeutics Stock
After touching a nearly four-year high of $173.25 on June 21, shares of biotech firm Sarepta Therapeutics Inc (NASDAQ:SRPT) steadily worked lower on the charts, touching a more than two-month low of $123.50 on Aug. 9.
Biotech Stock Flashing Bull Signal
Sarepta Therapeutics (SRPT) staged quite a slide after its June 21 three-year high of $173.25, closing six of the last seven weeks lower. The shares are in positive territory so far this week, however, as the stock extends a bounce off the $125 level.
2 Biotech Stocks to Buy Hand Over Fist in August
Vertex's newest approval and late-stage pipeline should yield stronger financial results. Smaller biotech Sarepta Therapeutics continues to innovate in its core therapeutic area.
Down -10.33% in 4 Weeks, Here's Why You Should You Buy the Dip in Sarepta Therapeutics (SRPT)
Sarepta Therapeutics (SRPT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Sarepta (SRPT) Q2 Earnings Top Estimates, Sales Lag, View Weak
Sarepta (SRPT) reports mixed results in the second quarter. It issues revenue guidance for 2025, which is below expectations.
Compared to Estimates, Sarepta Therapeutics (SRPT) Q2 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for Sarepta Therapeutics (SRPT) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
What Makes Sarepta Therapeutics (SRPT) a New Buy Stock
Sarepta Therapeutics (SRPT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Sarepta Therapeutics' Pullback After Recent FDA Approval A Buying Opportunity
Sarepta Therapeutics, Inc. is a leader in DMD treatment, with recent FDA approval for SRP-9001 gene therapy across all age groups. Despite a recent stock pullback, the company reported strong revenue growth and earnings, with a $130 billion cumulative U.S. revenue opportunity. The recent pullback is an attractive investment opportunity for long-term investors.
